MST1 and relapsing-remitting multiple sclerosis: We cannot determine whether the marked decrease in serum MST1 levels observed in RRMS patients compared to HC and other clinical forms contributes to immune dysregulation—primarily through Treg dysfunction, promoting a shift toward proinflammatory T cells that may drive neuroinflammation—or simply reflects its high concentration in T-cell-derived EVs, or both.